Abstract | AIM: MATERIALS AND METHODS: Forty one pediatric outpatients (27 females, mean age 14.5+/-1.4 ys) with H. pylori-associated chronic gastritis who underwent endoscopy for dyspeptic symptoms received the combination of bismuth subcitrate (8 mg/kg/day, q. d. s.) for 14 days, rifaximin (800 mg/day) for 10 days and furazolidone (10 mg/kg/day, q. d. s.) or nifuratel (15 mg/kg/two times daily) for 10 days. H. pylori status was determined before the treatment by modified Giemsa staining/ urease test and after the treatment (in 4-6 weeks) by ammonia breath test. RESULTS: H. pylori was eradicated in 35 children (85.4%; 95%CI: 75.4-96.4 ITT and PP tests). There were no serious adverse reactions and were no withdrawals due to any side effects. CONCLUSION:
|
Authors | A A Nizhevich, P L Shcherbakov, E N Akhmadeeva |
Journal | Eksperimental'naia i klinicheskaia gastroenterologiia = Experimental & clinical gastroenterology
(Eksp Klin Gastroenterol)
Issue 3
Pg. 98-100
( 2009)
ISSN: 1682-8658 [Print] Russia (Federation) |
PMID | 19928007
(Publication Type: Clinical Trial, Journal Article)
|
Chemical References |
- Anti-Infective Agents
- Organometallic Compounds
- Rifamycins
- Furazolidone
- bismuth tripotassium dicitrate
- Rifaximin
- Nifuratel
|
Topics |
- Adolescent
- Anti-Infective Agents
(administration & dosage, therapeutic use)
- Breath Tests
- Child
- Drug Therapy, Combination
- Female
- Furazolidone
(administration & dosage, therapeutic use)
- Helicobacter Infections
(drug therapy, microbiology)
- Helicobacter pylori
(drug effects, isolation & purification)
- Humans
- Male
- Nifuratel
(administration & dosage, therapeutic use)
- Organometallic Compounds
(administration & dosage, therapeutic use)
- Pilot Projects
- Rifamycins
(administration & dosage, therapeutic use)
- Rifaximin
- Treatment Outcome
|